Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital

RBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $112.00 (from $98.00) while maintaining an Outperform rating.

Analyst Brian Abrahams commented, "following a deep dive into the mechanism, preclinical data, competitive landscape, and mkt oppty for gene therapies in Duchenne muscular dystrophy (DMD), we are increasingly enthusiastic about the potential for SRPT's microdystrophin program and the likelihood they will report favorable initial NT results that will drive substantial stock upside."

You May Also Be Interested In

• EasyJet Plc. (EZJ:LN) (ESYJY) PT Raised to GBP750 at BofA Securities
• Viper Energy (VNOM) PT Raised to $41 at Roth/MKM
• UnitedHealth Group (UNH) PT Raised to $562 at Deutsche Bank